nach oben

Erschienen in:

01.07.2021 | Clinical Guides in Oncology

GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma

verfasst von: S. Gallego, D. Bernabeu, M. Garrido-Pontnou, G. Guillen, N. Hindi, A. Juan-Ribelles, C. Márquez, C. Mata, J. Orcajo, G. Ramírez, M. Ramos, C. Romagosa, D. Ruano, P. Rubio, R. Vergés, C. Valverde, GEIS (Grupo Español de Investigación en Sarcomas), SEHOP (Sociedad Española de Hematología y Oncología Pediátrica)

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma (STS) in children and adolescents. In Spain the annual incidence is 4.4 cases per million children < 14 years. It is an uncommon neoplasm in adults, but 40% of RMS are diagnosed in patients over 20 years of age, representing 1% of all STS in this age group. RMS can appear anywhere in the body, with some sites more frequently affected including head and neck, genitourinary system and limbs. Assessment of a patient with suspicion of RMS includes imaging studies (MRI, CT, PET-CT) and biopsy. All patients with RMS should receive chemotherapy, either at diagnosis in advanced or metastatic stages, or after initial resection in early local stages. Local control includes surgery and/or radiotherapy depending on site, stage, histology and response to chemotherapy. This guide provides recommendations for diagnosis, staging and treatment of this neoplasm.

https://www.skion.nl/workspace/uploads/Protocol-EpSSG-RMS-2005-1-3-May-2012_1.pdf.

Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;15(33):139–44.CrossRef

Garcia del Muro X, de Alava E, Artigas V, Bague S, Braña A, Cubedo R, Spanish Group for Research on Sarcoma, et al. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS). Cancer Chemother Pharmacol. 2016;77:133–46.PubMedCrossRef

Pardo Romaguera E, Muñoz López A, Valero Poveda S, Porta Cebolla S, Barreda Reines MS, Fernández Delgado R, et al. Cáncer infantil en España. Estadísticas 1980–2018. Registro Español de Tumores infantiles (RETI-SEHOP). 2019.

Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995 National Cancer Institute SEER Program. Bethesda: NIH Pub No. 99-4649; 1999.

Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49:684–95.PubMedCrossRef

Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2600 patients. J Clin Oncol. 2009;27:3391–7.PubMedCrossRef

Nakata K, Ito Y, Magadi W, Bonaventure A, Stiller CA, Katanoda K, et al. Childhood cancer incidence and survival in Japan and England: a population-based study (1993–2010). Cancer Sci. 2018;109:422–34.PubMedCrossRef

Stiller CA, Parkin DM. International variations in the incidence of childhood soft-tissue sarcomas. Paediatr Perinat Epidemiol. 1994;8:107–19.PubMedCrossRef

10.

Nichols KE, Malkin D, Garber JE, Li FP. Germ line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomark Prev. 2001;10:83–7.

11.

Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5:1.PubMedPubMedCentralCrossRef

12.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69:7–34.CrossRef

13.

Freling NJM, Merks JHM, Saeed P, Balm AJM, Bras J, Pieters BR, et al. Imaging findings in craniofacial childhood rhabdomyosarcoma. Pediatr Radiol. 2010;20(40):1723–38.CrossRef

14.

McCarville MB, Spunt SL, Pappo AS. Rhabdomyosarcoma in pediatric patients: the good, the bad and the unusual. Am J Roentgenol. 2001;176:1563–9.CrossRef

15.

Hayes-Jordan A, Andrassy R. Rhabdomyosarcoma in children. Curr Opin Pediatr. 2009;21:373–8.PubMedCrossRef

16.

Park K, van Rijn R, McHugh K. The role of radiology in paediatric soft tissue sarcomas. Cancer Imaging. 2008;8:102–15.PubMedPubMedCentralCrossRef

17.

Inarejos Clemente EJ, Navallas M, Martínez B, de la Torre I, Suñol M, Munuera Del Cerro J, Torner F, et al. MRI of rhabdomyosarcoma and other soft-tissue sarcomas in children. Radiographics. 2020;40:791–814.PubMedCrossRef

18.

Saboo SS, Krajewski KM, Zukotynski K, Howard S, Jagannathan JP, Hornick JL, et al. Imaging features of primary and secondary adult rhabdomyosarcoma. Am J Roentgenol. 2012;199:W694-703.CrossRef

19.

van Vliet M, Kliffen M, Krestin GP, van Dijke CF, Vliet M, Kliffen M, et al. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol. 2009;19:1499–511.PubMedCrossRef

20.

El-Kholy E, El Nadi E, Hafez H, Ahmed S, Younes A, El-Kenanii N, et al. Added predictive value of 18F-FDG PET/CT for pediatric rhabdomyosarcoma. Nucl Med Commun. 2019;40:898–904.PubMedCrossRef

21.

Sa R, Liu D, Zhao H, Hou S, Lin Q, Guan F. Utility of [(18)F] fluoro-deoxyglucose positron emission tomography/computed tomography for staging and therapy response evaluation in pediatric rhabdomyosarcoma: a case series and literature review. Front Med (Lausanne). 2020;7:281.CrossRef

22.

Berger-Richardson D, Swallow CJ. Needle tract seeding after percutaneous biopsy of sarcoma: risk/benefit considerations. Cancer. 2017;123:560–7.PubMedCrossRef

23.

Barrientos-Ruiz I, Ortiz-Cruz EJ, Serrano-Montilla J, Bernabeu-Taboada D, Pozo-Kreilinger JJ. Are biopsy tracts a concern for seeding and local recurrence in sarcomas? Clini Orthop Relat Res. 2017;475(2):511–8.CrossRef

24.

Chowdhury T, Barnacle A, Haque S, Sebire N, Gibson S, Anderson J, et al. Ultrasound-guided core needle biopsy for the diagnosis of rhabdomyosarcoma in childhood. Pediatr Blood Cancer. 2009;53(3):356–60.PubMedCrossRef

25.

Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013;20:387–97.PubMedPubMedCentralCrossRef

26.

Alaggio R, Zhang L, Sung YS, Huang SC, Chen CL, Bisogno G, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40:224–35.PubMedPubMedCentralCrossRef

27.

Mosquera JM, Sboner A, Zhang L, Kitabayashi N, Chen CL, Sung YS, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52:538–50.PubMedCrossRef

28.

Agaram NP, LaQuaglia MP, Alaggio R, Zhang L, Fujisawa Y, Ladanyi M, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32:27–36.PubMedCrossRef

29.

Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020;33:404–19.PubMedCrossRef

30.

Hibbitts E, Chi YY, Hawkins DS, Barr FG, Bradley JA, Dasgupta R, et al. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: a report from the Children’s Oncology Group. Cancer Med. 2019;8:6437–48.PubMedPubMedCentralCrossRef

31.

Freling NJM, Merks JHM, Saeed P, Balm AJM, Bras J, Pieters BR, et al. Imaging findings in craniofacial childhood rhabdomyosarcoma. Pediatr Radiol. 2010;40:1723–38.PubMedPubMedCentralCrossRef

32.

Jawad N, McHugh K. The clinical and radiologic features of paediatric rhabdomyosarcoma. Pediatr Radiol. 2019;49:1516–23.PubMedCrossRef

33.

Norman G, Fayter D, Lewis-Light K, Chisholm J, McHugh K, Levine D, et al. An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open. 2015;5:e006030.PubMedPubMedCentralCrossRef

34.

Wagner LM, Kremer N, Gelfand MJ, Sharp SE, Turpin BK, Nagarajan R, et al. Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-A prospective trial. Cancer. 2017;123:155–60.PubMedCrossRef

35.

Bethesda MD. PDQ Childhood Rhabdomyosarcoma Treatment. National Cancer Institute. 2020. https://www.cancer.gov/types/softtissuesarcoma/hp/rhabdomyosarcoma-treatment-pdq. Accessed 12 July 2020.

36.

Lim HJ, Johnny Ong CA, Tan JW, Ching Teo MC. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: a systematic review. Crit Rev Oncol Hematol. 2019;143:1–13.PubMedCrossRef

37.

Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435–41.PubMedCrossRef

38.

Gennaro N, Marrari A, Renne SL, Cananzi FCM, Quagliuolo VL, Di Brina L, et al. Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging. Br J Radiol. 2020;93:20200250.PubMedPubMedCentralCrossRef

39.

Terwisscha van Scheltinga SEJ, Wijnen M, Martelli H, Rogers T, Mandeville H, Gaze MN, et al. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study. Cancer Med. 2020;9:7580–9.PubMedPubMedCentralCrossRef

40.

Federico SM, Spunt SL, Krasin MJ, Billup CA, Wu J, Shulkin B, et al. Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer. 2013;60:1128–34.PubMedCrossRef

41.

National Cancer Institute. Sentinel Lymph Node Biopsy. 2011

42.

Parida L, Morrisson GT, Shammas A, Hossain AKM, McCarville MB, Gerstle T, et al. Role of lymphoscintigraphy and sentinel lymph node biopsy in the management of pediatric melanoma and sarcoma. Ped Surg Int. 2012;28:571–8.CrossRef

43.

Rogers T, Smeele L, Scheltinga STV, Corti FD, Guillén Burrieza G, Smeulders N, et al. Surgery guidelines rhabdomyosarcoma, long version, FaRMS protocol, EpSSG [Internet]. https://www.epssgassociation.it/en/.

44.

Weiss AR, Lyden ER, Anderson JR, Hawkins DS, Spunt SL, Walterhouse DO, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol. 2013;31:3226.PubMedPubMedCentralCrossRef

45.

Lawrence W, Anderson JR, Gehan EA, Maurer H. Pretreatment TNM staging of childhood rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Cancer. 1997;80:1165–70.PubMedCrossRef

46.

Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol. 2012;30:1670–7.PubMedCrossRef

47.

Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AD, Paidas CN, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol. 2009;27:5182–8.PubMedPubMedCentralCrossRef

48.

Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Childrens Oncology Group. J Clin Oncol. 2018;36:2770–7.PubMedPubMedCentralCrossRef

49.

Oberlin O, Rey A, Sanchez de Toledo J, Jenney JEM, Scopinaro M, Bergeron C, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol. 2012;30:2457–65.PubMedCrossRef

50.

Ferrari A, Bisogno G, Casanova M, Meazza C, Piva L, Cecchetto G, et al. Paratesticular rhabdomyosarcoma: report from the Italian and German Cooperative Group. J Clin Oncol. 2002;20:449–55.PubMedCrossRef

51.

Bisogno G, Jenney M, Bergeron C, Gallego Melcon S, Ferrari A, Oberlin O, et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol. 2018;19:1061–71.PubMedCrossRef

52.

Gallego S, Zanetti I, Orbach D, Ranchere D, Shipley J, Zin A, et al. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer. 2018;124:3201–9.PubMedCrossRef

53.

Bisogno G, de Salvo GL, Bergeron C, Gallego G, Merks JM, Kelsey A, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:1566–75.PubMedCrossRef

54.

Cecchetto G, Bisogno G, De Corti F, Dall’Igna P, Inserra A, Ferrari A, et al. Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: The experience of the Italian Cooperative Group studies. Cancer. 2007;110:2561–7.PubMedCrossRef

55.

Schmidt A, Warmann SW, Eckert F, Ellerkamp V, Schaefer J, Blumenstock G, et al. The role of reconstructive surgery and brachytherapy in pediatric bladder/prostate rhabdomyosarcoma. J Urol. 2020;204:825–34.PubMedCrossRef

56.

Chargari C, Haie-Meder C, Guérin F, Minard-Colin V, de Lambert G, Mazeron R, et al. Brachytherapy combined with surgery for conservative treatment of children with bladder neck and/or prostate. Int J Radiat Oncol Biol Phys. 2017;98:352–9.PubMedCrossRef

57.

Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003;98:571–80.PubMedCrossRef

58.

Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384–9.PubMedPubMedCentralCrossRef

59.

Bergamaschi L, Bertulli R, Casanova M, Provenzano S, Chiaravalli S, Gasparini P, et al. Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single-center series. Med Oncol. 2019;36:59.PubMedCrossRef

60.

Malempati S, Weigel BJ, Chi YY, Tian J, Anderson JR, Parham DM, et al. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer. 2019;125:290–7.PubMedCrossRef

61.

McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer. 2010;46:1588–95.PubMedCrossRef

62.

Bergeron C, Thiesse P, Rey A, Orbach D, Boutard P, Thomas C, et al. Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer. 2008;44:427–31.PubMedCrossRef

63.

Peinemann F, Kröger N, Bartel C, Grouven U, Pittler M, Erttmann R, et al. High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma—a systematic review. PLoS ONE. 2011;6:e17127.PubMedPubMedCentralCrossRef

64.

Arush MB, Minard-Colin V, Mosseri V, Defachelles AS, Bergeron C, Algret N, et al. Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? Eur J Cancer. 2015;51:193–201.PubMedCrossRef

65.

Mohan AC, Venkatramani R, Okcu MF, Nuchtern JG, Vasudevan SA, Mahajan A, et al. Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood Cancer. 2018;65:e26859.CrossRef

66.

Liu AK, Stinauer M, Albano E, Greffe B, Tello T, Maloney K. Local control of metastatic sites with radiation therapy in metastatic Ewing sarcoma and rhabdomyosarcoma. Pediatr Blood Cancer. 2011;57:169–71.PubMedCrossRef

67.

Cameron A, Chisholm J, Elze MC, Casanova M, Geoerger B, Gaze M. Role of radiotherapy to primary/metastatic sites in pediatric patients with metastatic rhabdomyosarcoma in the BERNIE study. J Clin Oncol. 2017;35(suppl):10541.CrossRef

68.

Schoot RA, McHugh K, Van Rijn RR, Kremer LCM, Chisholm JC, Caron HN, et al. Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology. 2013;269:870–8.PubMedCrossRef

69.

Orsatti G, Beltrame V, Crimì F, Frigo AC, Bisogno G, Stramare R. Radiologic response assessment in pediatric soft tissue sarcoma: computed-assisted volume evaluation. J Pediatr. 2017;182:327-334.e2.PubMedCrossRef

70.

Rosenberg AR, Anderson JR, Lyden E, Rodeberg DA, Wolden SL, Kao SC, et al. Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children’s Oncology Group. Eur J Cancer. 2014;50(4):816–23.PubMedCrossRef

71.

Casey DL, Wexler LH, Fox JJ, Dharmarajan KV, Schoder H, Price AN, et al. Predicting outcome in patients with rhabdomyosarcoma: role of (18)FDG positron emission tomography. Int J Radiat Oncol Biol Phys. 2014;90:1136–42.PubMedCrossRef

72.

Voss SD. Functional and anatomical imaging in pediatric oncology: which is best for which tumors. Pediatr Radiol. 2019;49:1534–44.PubMedCrossRef

73.

Pourmehdi Lahiji A, Jackson T, Nejadnik H, von Eyben R, Rubin D, Spunt SL, et al. Association of tumor [(18)F]FDG activity and diffusion restriction with clinical outcomes of rhabdomyosarcomas. Mol Imaging Biol. 2019;21:591–8.PubMedCrossRef

74.

Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins DS, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17:3487–93.PubMedCrossRef

75.

Lager JJ, Lyden ER, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol. 2006;24:3415–22.PubMedCrossRef

76.

Mascarenhas L, Lyden ER, Breitfeld PP, Walterhouse DO, Donaldson SS, Paidas CN, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2010;28:4658–63.PubMedPubMedCentralCrossRef

77.

Defachelles AS, Bogart E, Casanova M, Merks H, Bisogno G, Calareso G, et al. Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS ASCO 2019 (Abstract #250271). J Clin Oncol. 2019. https://doi.org/10.1200/JCO.2019.37.15_suppl.10000.CrossRef

78.

Chisholm JC, Machin D, McDowell H, McHugh K, Ellershaw C, Jenney M, et al. Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed of metastatic soft tissue sarcoma. Eur J Cancer. 2007;43:2537–44.PubMedCrossRef

79.

Casanova M, Ferrari A, Bisogno G, Merks JHM, De Salvo GL, Meazza C, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer. 2004;101:1664–71.PubMedCrossRef

80.

Saylors RL, Stine KC, Sullivan J, Kepner JL, Bernstein ML, Harris MB, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–9.PubMedCrossRef

81.

Hayes-Jordan A, Doherty DK, West SD, Raney RB, Blakely ML, Cox CS, et al. Outcome after surgical resection of recurrent rhabdomyosarcoma. J Pediatr Surg. 2006;41:633–8.PubMedCrossRef

82.

Dantonello TM, Int-Veen C, Schuck A, Seitz G, Leuschner I, Nathrath M, et al. Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma: recurrent alveolar rhabdomyosarcoma outcomes. Pediatr Blood Cancer. 2013;60:1267–73.PubMedCrossRef

83.

Susa M, Kikuta K, Nakayama R, Nishimoto K, Horiuchi K, Oguro S, et al. CT guided cryoablation for locally recurrent or metastatic bone and soft tissue tumor: Initial experience. BMC Cancer [Internet]. 2016;16:798.CrossRef

84.

Grilley-Olson JE, Webber NP, Demos DS, Christensen JD, Kirsch DG. Multidisciplinary management of oligometastatic soft tissue sarcoma. Am Soc Clin Oncol Educ B. 2018;38:939–48.CrossRef

85.

Dantonello TM, Int-Veen C, Winkler LI, Schuck A, Schmidt BF, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma tobias. J Clin Oncol. 2008;26:406–13.PubMedCrossRef

86.

Hammond WJ, Farber BA, Price AP, Wolden SL, Heaton TE, Wexler LH, et al. Paratesticular rhabdomyosarcoma: importance of initial therapy. J Pediatr Surg. 2017;52:304–8.PubMedCrossRef

87.

Bradley JA, Indelicato DJ, Uezono H, Morris CG, Sandler E, de Soto H, et al. Patterns of failure in parameningeal alveolar rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2020;107:325–33.PubMedCrossRef

88.

Vaarwerk B, Mallebranche C, Affinita MC, van der Lee JH, Ferrari A, Chisholm JC, et al. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? Eur Exp Cancer. 2020;125:823–31.

89.

Bate J, Wingrove J, Donkin A, Taylor R, Whelan J. Patient perspectives on a national multidisciplinary team meeting for a rare cancer. Eur J Cancer Care. 2019;28:12971.CrossRef

90.

Blay JY, Sleijfer S, Schöffski P, Kawai A, Brodowicz T, Demetri GD, Maki RG. International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer. 2014;50:679–89.PubMedCrossRef

91.

Punyko JA, Gurney JG, Scott Baker K, Hayashi RJ, Hudson MM, Liu Y, et al. Physical impairment and social adaptation in adult survivors of childhood and adolescent rhabdomyosarcoma: a report from the Childhood Cancer Survivors Study. Psychooncology. 2007;16:26–37.PubMedCrossRef

92.

Vaarwerk B, Schoot RA, Maurice-Stam H, Slater O, Hartley B, Saeed P, et al. Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma. Pediatr Blood Cancer. 2019;66:e27498.PubMedCrossRef

93.

Tonning Olsson I, Brinkman TM, Wang M, Ehrhardt MJ, Banerjee P, Mulrooney DA, et al. Neurocognitive and psychosocial outcomes in adult survivors of childhood soft-tissue sarcoma: a report from the St Jude Lifetime Cohort. Cancer. 2020;126:1576–84.PubMedCrossRef

Titel: GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma
verfasst von: S. Gallego
D. Bernabeu
M. Garrido-Pontnou
G. Guillen
N. Hindi
A. Juan-Ribelles
C. Márquez
C. Mata
J. Orcajo
G. Ramírez
M. Ramos
C. Romagosa
D. Ruano
P. Rubio
R. Vergés
C. Valverde
GEIS (Grupo Español de Investigación en Sarcomas), SEHOP (Sociedad Española de Hematología y Oncología Pediátrica)
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-021-02654-1

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics

Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes

Short-course radiotherapy in stage IV rectal cancer with resectable disease

Immunotherapy in AML: a brief review on emerging strategies

Surgical resection of primary tumor in the extremities improves survival for metastatic soft-tissue sarcoma patients: a population-based study of the SEER database

Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie